Teva, Intel partner on machine learning tech for Huntington’s Disease
Israeli pharmaceutical firm Teva is partnering with US chipmaker Intel to develop wearables and a machine learning platform that can be used in the treatment of Huntington’s Disease. What’s Hot on ZDNet Huntington’s is a genetic and typically fatal neurodegenerative disease that causes nerve cells in the brain to deteriorate. This leads to a host of behavioral and psychological problems, including involuntary writhing movements called chorea. Patients generally succumb to the disease within 15 to 25 years of the diagnosis. There is no cure for Huntington’s, but Teva and Intel hope to spur the development of next-gen treatment options by better understanding the progression of the disease and how current treatments impact a patients’ quality of life. The companies plan to accomplish this by combining Intel’s capabilities in analytics and…
Link to Full Article: Teva, Intel partner on machine learning tech for Huntington’s Disease
Sharing
